JPRN-jRCT2080220563未知3 期
Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase III Study>
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •- Patient meets DSM-IV criteria for schizophrenia.
- •- Patient is 18 or older but younger than 75 years of age on the day of signing informed consent.
- •- Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.
排除标准
- •- Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
- •- Patient has Parkinson's disease.
- •- Patient has a history or complication of malignancy.
研究者
相似试验
进行中（未招募）
不适用
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 - 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisMultiple sclerosisMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2006-002633-20-ITGlaxoSmithKline Research & Development Ltd350
进行中（未招募）
不适用
Subcutaneous Ofatumumab in Relapsing Remitting Multiple Sclerosis.Relapsing-Remitting Multiple Sclerosis (RRMS).MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002333-19-ITGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.196
进行中（未招募）
不适用
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisEUCTR2006-002633-20-NLGlaxoSmithKline Research & Development Ltd350
进行中（未招募）
不适用
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 8.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2006-002633-20-FIGlaxoSmithKline Research & Development Ltd350
进行中（未招募）
1 期
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2006-002633-20-GBGlaxoSmithKline Research & Development Ltd